Asacol Leadership
Asacol Delivers Leadership Through a Wealth of Evidence and Experience
Asacol Delivers Leadership Through a Wealth of Evidence and Experience
Confidence in your therapy choice is important when choosing an Ulcerative Colitis medication.
* July 1, 2007-June 30, 2008.
† This information is an estimate derived from the use of information under license from the following IMS National Prescription Data for the12-month period ending January 2008. IMS expressly reserves all rights, including rights of copying, distribution, and republication.
‡ IMS National Prescription Data from 1992-July 2006.
§ American Gastroenterological Association.
|| Crohn's & Colitis Foundation of America.
¶ Verispan Managed Care Formulary Drug Audit, spring 2008. The spring 2008 data represent an estimated 63%of all US HMO subscribers whose prescription benefits are controlled by formularies.
References: 1. Data on file, Procter & Gamble Pharmaceuticals, Inc.Selected Safety Information
Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35% vs 36%), abdominal pain (18% vs 14%), and eructation (16% vs 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs 50%), rhinitis (42% vs 36%) , and diarrhea (35% vs 50%).
Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol.
Please see accompanying full prescribing information by clicking the link above.
